Observational studyFrontiers in endocrinology2026
PGT-A versus expectant management for fertile patients with recurrent pregnancy loss and prior aneuploidy: a dual-center, real-world study of 5-year cumulative pregnancy outcomes.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study evaluated the effectiveness and cost-effectiveness of preimplantation genetic testing for aneuploidy (PGT-A) versus expectant management (EM) for achieving live birth among fertile patients with recurrent pregnancy loss (RPL) and prior aneuploid pregnancy loss. Methods: This dual-center retrospective cohort study included 216 fertile patients with RPL and at least one previous aneuploid pregnancy loss. Seventy-one patients chose EM and 145 chose PGT-A. Propensity score matching (PSM), multivariable logistic regression, and subgroup analyses were performed. The primary outcome was conception leading to live birth (CLLB) within 12 months. Secondary outcomes included CLLB at 24 and 36 months, cumulative live birth (CLB) at 5 years, time to pregnancy leading to live birth (TPLB), early miscarriage per clinical pregnancy, and incremental cost-effectiveness ratios (ICERs). Results: After PSM, 71 matched pairs were analyzed. CLLB within 12 months was lower in the PGT-A group than in the EM group (52.1% vs. 81.7%; adjusted odds ratio 0.27, 95% confidence interval 0.13-0.53; P < 0.001). Five-year CLB rates were similar (94.4% vs. 87.3%; P = 0.15), whereas TPLB was longer with PGT-A (median 8.6 vs. 3.0 months; P < 0.001). Early miscarriage rates per clinical pregnancy did not differ significantly (7.4% vs. 12.4%; adjusted odds ratio 0.42; P = 0.09). The ICERs per additional live birth and per miscarriage prevented were ¥1,203,800 and ¥1,504,800, respectively. Discussion: In fertile patients with RPL and prior aneuploidy, PGT-A and EM were associated with similar 5-year cumulative live birth rates, whereas EM was associated with a higher probability of CLLB within 12 months and a shorter TPLB. A possible reduction in miscarriage with PGT-A remains uncertain and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.